InvestorsHub Logo
Followers 335
Posts 18989
Boards Moderated 0
Alias Born 08/25/2007

Re: zino post# 7553

Wednesday, 09/13/2017 11:20:38 AM

Wednesday, September 13, 2017 11:20:38 AM

Post# of 8299
To Potential Buyers Levosimendin Phase3 Still Has Value
http://www.tenaxthera.com/research/levo-cts/levo-cts-overview/

Levosimendin demonstrated statistically significant reductions in two of three secondary endpoints including:
Reduction in low cardiac output syndrome (LCOS)
Reduction in postoperative use of secondary inotropes.


DONT LISTEN TO ME IM CANADIANNNNNNNN

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TENX News